×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Age Related Macular Degeneration Market

ID: MRFR/Pharma/4281-CR
200 Pages
Rahul Gotadki
July 2025

Marché de la dégénérescence maculaire liée à l'âge : informations par type (dégénérescence maculaire humide liée à l'âge (DMLA humide) et dégénérescence maculaire liée à l'âge sec (DMLA sèche)) stade (dégénérescence maculaire liée à l'âge au stade intermédiaire, dégénérescence maculaire liée à l'âge à un stade précoce et dégénérescence maculaire liée à l'âge à un stade avancé) Groupe d'âge (plus de 75 ans, plus de 60 ans et plus de 40 ans) par traitement (traitement et diagnostic) Voie d'administration (voie d... lire la suite

Partager
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Age Related Macular Degeneration Market Infographic
Purchase Options

Age Related Macular Degeneration Market Résumé

Les principales entreprises du marché Age Related Macular Degeneration Market incluent

Portée du rapport

Faits saillants du marché

Auteur
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Laisser un commentaire

FAQs

What is the projected market valuation for Age-Related Macular Degeneration by 2035?

The projected market valuation for Age-Related Macular Degeneration is expected to reach 20.59 USD Billion by 2035.

What was the market valuation for Age-Related Macular Degeneration in 2024?

The overall market valuation for Age-Related Macular Degeneration was 8.45 USD Billion in 2024.

What is the expected CAGR for the Age-Related Macular Degeneration market from 2025 to 2035?

The expected CAGR for the Age-Related Macular Degeneration market during the forecast period 2025 - 2035 is 8.43%.

Which treatment method is projected to have the highest market value by 2035?

Anti-VEGF Therapy is projected to have the highest market value, expected to grow from 3.5 USD Billion to 8.5 USD Billion.

What are the key players in the Age-Related Macular Degeneration market?

Key players in the market include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, Pfizer, Alcon, Horizon Therapeutics, Apellis Pharmaceuticals, and Santen Pharmaceutical.

How does the market for Dry Age-Related Macular Degeneration compare to Wet Age-Related Macular Degeneration?

The market for Dry Age-Related Macular Degeneration is expected to grow from 3.38 USD Billion to 8.0 USD Billion, while Wet Age-Related Macular Degeneration is projected to increase from 4.23 USD Billion to 9.8 USD Billion.

What distribution channel is anticipated to show significant growth by 2035?

Online Pharmacies are anticipated to show significant growth, with a projected increase from 2.12 USD Billion to 5.3 USD Billion.

Which patient demographic is expected to dominate the Age-Related Macular Degeneration market?

Elderly Patients are expected to dominate the market, with a projected growth from 3.5 USD Billion to 8.5 USD Billion.

What is the expected market value for Nutritional Supplements by 2035?

The expected market value for Nutritional Supplements is projected to rise from 2.45 USD Billion to 6.09 USD Billion by 2035.

How does the market for Optical Clinics compare to Retail Pharmacies in terms of growth?

The market for Optical Clinics is expected to grow from 1.69 USD Billion to 4.05 USD Billion, whereas Retail Pharmacies are projected to increase from 2.12 USD Billion to 5.12 USD Billion.

Télécharger l'échantillon gratuit

Veuillez remplir le formulaire ci-dessous pour recevoir un échantillon gratuit de ce rapport

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions